Search results for "GFR"

showing 6 items of 206 documents

Serum Uric Acid and Kidney Disease Measures Independently Predict Cardiovascular and Total Mortality: The Uric Acid Right for Heart Health (URRAH) Pr…

2021

Background: Serum uric acid predicts the onset and progression of kidney disease, and the occurrence of cardiovascular and all-cause mortality. Nevertheless, it is unclear which is the appropriate definition of hyperuricemia in presence of chronic kidney disease (CKD). Our goal was to study the independent impact of uric acid and CKD on mortality.Methods: We retrospectively investigated 21,963 patients from the URRAH study database. Hyperuricemia was defined on the basis of outcome specific cut-offs separately identified by ROC curves according to eGFR strata. The primary endpoints were cardiovascular and all-cause mortality.Results: After a mean follow-up of 9.8 year, there were 1,582 (7.2…

medicine.medical_specialtyhyperuricemiaCardiovascular Medicineurologic and male genital diseasesGastroenterologyalbuminuriachemistry.chemical_compoundcardiovascular mortalityInternal medicinemedicineeGFRDiseases of the circulatory (Cardiovascular) systemHyperuricemiaRisk factorOriginal Researchbusiness.industryIncidence (epidemiology)Confoundingalbuminuria; all-cause mortality; cardiovascular mortality; eGFR; hyperuricemiahyperuricemia eGFR albuminuria cardiovascular mortality all-cause mortalitymedicine.diseasechemistryQuartileRC666-701AlbuminuriaUric acidall-cause mortalitymedicine.symptomCardiology and Cardiovascular MedicinebusinessKidney disease
researchProduct

Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.

2015

Abstract: Introduction: The identification of cell membrane-bound molecules with a relevant role in cancer cell survival prompted the development of moAbs to block the related pathways. In the last few years, the number of approved moAbs for cancer treatment has constantly increased. Many of these drugs significantly improved the survival outcomes in patients with solid tumours. Areas covered: In this review, all the FDA-approved moAbs in solid tumours have been described. This is an update of moAbs available for cancer treatment nowadays in comparison with the moAbs approved until few years ago. The moAbs under development are also discussed here. Expert opinion: The research on cancer ant…

medicine.medical_treatmentClinical BiochemistryCellReceptor activator of nuclear factor κB ligandCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)NeoplasmsMonoclonalDrug DiscoveryDrug approvalCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all); Cancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)Drug ApprovalCancerbiologyMedicine (all)Antibodies MonoclonalVEGFReceptor activator of nuclear factor κB ligandmedicine.anatomical_structureMonoclonalMoAbsImmunotherapyAntibodyEngineering sciences. TechnologyHumanUnited StateCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)medicine.drug_classEGFRMonoclonal antibodyAntibodiesCancer antigenCytotoxic T-lymphocyte antigen 4HER2medicineHumansBiologyPharmacologybusiness.industryUnited States Food and Drug AdministrationDrug Discovery3003 Pharmaceutical ScienceCancerImmunotherapymedicine.diseaseUnited StatesImmunologyCancer cellCancer researchbiology.proteinNeoplasmMoAbHuman medicinebusinessExpert opinion on biological therapy
researchProduct

Is COVID‐19 infection more severe in kidney transplant recipients?

2021

International audience; There are no studies which have compared the risk of severe Covid-19 and related mortality between transplant recipients and non-transplant patients. We enrolled two groups of patients hospitalized for Covid-19, i.e., kidney transplant recipients from the French Registry of Solid Organ Transplant (n=306) and a single-center cohort of non-transplant patients (n=795). An analysis was performed among subgroups matched for age and risk factors for severe Covid-19 or mortality. Severe Covid-19 was defined as admission (or transfer) to an intensive care unit, need for mechanical ventilation, or death.Transplant recipients were younger and had more comorbidities compared to…

medicine.medical_treatment[SDV]Life Sciences [q-bio]MESH: Registries*AucunMESH: Comorbidity030230 surgerylaw.inventionchemistry.chemical_compound0302 clinical medicinelawcardiovascular diseaseMESH: Risk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesclinical research / practiceImmunology and AllergyCumulative incidencePharmacology (medical)kidney transplantation / nephrologyMESH: IncidenceMESH: AgedUnivariate analysisMESH: France / epidemiologyMESH: Middle AgedMESH: Transplant Recipients / statistics & numerical data*Acute kidney injuryIntensive care unit3. Good healthMESH: COVID-19 / epidemiologyCohort[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesglomerular filtration rate (GFR)kidney failure / injurymedicine.medical_specialtyinfection and infectious agents - viralinfectious diseaseBrief CommunicationMESH: Graft Rejection / prevention & control03 medical and health sciencesInternal medicineDiabetes mellitusMESH: Severity of Illness IndexMESH: COVID-19 / diagnosis*medicineHumansMESH: SARS-CoV-2Mechanical ventilationCreatinineTransplantationMESH: Humansbusiness.industrySARS-CoV-2MESH: Graft Rejection / epidemiology*COVID-19MESH: Retrospective Studiesmedicine.diseaseKidney TransplantationTransplant RecipientsMESH: Maleimmunosuppressive regimensMESH: Immunosuppressive Agents / therapeutic useMESH: Pandemics*MESH: Propensity Score*chemistryReinfectionMESH: Immunosuppression / methodsMESH: Intensive Care UnitsbusinessMESH: FemaleMESH: Kidney Transplantation*
researchProduct

Impacto del miRNA-200c sobre el mecanismo de migración celular en el glioblastoma.Relación con los patrones de amplificación de EGFR.

2016

El Glioblastoma Multiforme (GB), la neoplasia primaria del SNC más importante en adultos, por su frecuencia y agresividad, se muestra como paradigmática de los procesos de infiltración y angiogénesis en las neoplasias. Su localización en el sistema nerviosos central, su alta capacidad invasiva y las consecuencias de una angiogénesis displasica hacen del GB una enfermedad neoplásicas altamente invalidante y de evolución fatal, en la que las distintas acciones terapéuticas se muestran ineficaces. Este trabajo realiza un estudio clínico, morfológico ,genético y epigenético de 46 casos de GB primarios. Se describe un grupo de miRNAs no descritos anteriormente en el GB. Se estableció la correlac…

migraciónmirna-200cglioblastomaamplificación egfr
researchProduct

The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer

2019

personalized therapysyöpähoidotEGFRprecision medicinebiopsiaDNActDNAdiagnostiikkata3111ta3122verenkiertoNSCLCkeuhkosyöpäsyöpäsolutmarkkeritcancerFrontiers in Oncology
researchProduct

Katsomisen hierarkiat ja kuinka niitä murretaan : valokuvateoksen rooli suomalaisessa yhteisötaiteessa

2012

Tutkielmassa tarkastellaan taideteoksen roolia suomalaisessa yhteisötaiteessa saksalaisen kriittisen koulukunnan näkökulmasta. Yhteisötaide on 1990-luvulta alkaen vahvistunut taidemuoto, jossa taiteilija työskentelee yhdessä tietyn ihmisryhmän kanssa. Ensimmäisiä yhteisötaideprojekteja Suomessa toteutettiin 1970-luvulla lähiöissä. 2000-luvulla yhteisötaiteessa on alettu käyttää ilmaisumuotona valokuvaa. Tässä tutkielmassa esimerkkeinä käytetään teoksia Maailman ihanin tyttö, Lempipaikka ja Be your enemy. Tutkijoista esimerkkeinä käytetään Mika Hannulan, Helena Sederholmin ja Lea Kantosen teorioita ja taiteilijoista Miina Savolaisen, Teemu Mäen ja Lea Kantosen näkökulmia. Tavoitteena on osoi…

valokuvataideyhteisötaidetaideteoksetKracauer SiegfriedAdorno Theodor WBenjamin WalterFreire Pauloroolit
researchProduct